Reference ID: 3537640 - Food and Drug Administration
C-tavaborole solution, tavaborole conjugates and metabolites were shown to be excreted primarily in the urine. The pharmacokinetics of tavaborole was investigated in 24 subjects with distal subungual onychomycosis
Tags:
Administration, Drug, Food and drug administration, Food, Reference, Onychomycosis, Reference id, 3537640
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
Reference ID: 3101735 - Food and Drug …
www.accessdata.fda.govDocetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govDacogen is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and …
Effexor (venlafaxine hydrochloride) Tablets …
www.accessdata.fda.govEffexor ® (venlafaxine hydrochloride) Tablets Rx only . Suicidality and Antidepressant Drugs Antidepressants increased the risk compared …
Tablets, Antidepressant, Effexor, Venlafaxine hydrochloride, Venlafaxine, Hydrochloride
Cytotec® - Food and Drug Administration
www.accessdata.fda.govcytotec® (misoprostol) warnings cytotec (misoprostol) administration to women who are pregnant can cause abortion, premature birth, or birth defects.
Administration, Drug, Food and drug administration, Food, Cytotec
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govweakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms . FULL …
Namenda XR (memantine hydrochloride) capsules …
www.accessdata.fda.govThe most commonly observed adverse reactions seen in patients administered NAMENDA XR in the controlled clinical trial, defined as those occurring at a frequency of at least 5% in the
Clinical, Capsule, Hydrochloride, Namenda xr, Namenda, Memantine hydrochloride, Memantine
FOR INTRAVENOUS USE ONLY - Food and Drug …
www.accessdata.fda.govNDA 50-706/S-022 Page 3 MERREM® I.V. (meropenem for injection) FOR INTRAVENOUS USE ONLY To reduce the development of drug-resistant bacteria and maintain the effectiveness of
Drug, Food, Food and drug, Only, Intravenous, For intravenous use only
NOT FOR USE IN NEONATES CONTAINS BENZYL …
www.accessdata.fda.govDepo-Medrol® methylprednisolone acetate injectable suspension, USP NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL . Not For Intravenous Use . DESCRIPTION
Alcohols, Neonates, Contains, In neonates contains benzyl, Benzyl, In neonates contains benzyl alcohol
Venofer - Food and Drug Administration
www.accessdata.fda.govNDA 21-135/S-017 Page 3 Venofer ® (iron sucrose injection, USP) Rx Only DESCRIPTION Venofer® (iron sucrose injection, USP) is a brown, sterile, aqueous, complex of …
Administration, Drug, Food and drug administration, Food, Only, Venofer
Diphenhydramine Hydrochloride Injection
www.accessdata.fda.govHOW SUPPLIED Diphenhydramine Hydrochloride Injection, USP is a clear and colorless solution available as: 50 mg/mL in a 1 mL prefilled single-use syringe.
Related documents
PRODUCT INFORMATION Tinasil - Medicines
www.medicines.org.auTinasil – Product Information 5 Fluconazole significantly increased the C max and AUC of terbinafine, due to inhibition of both CYP2C9 and CYP3A4 enzymes. Similar increase in exposure may occur when other drugs which inhibit both CYP2C9 and
Formulary Exception/Prior Authorization Request Form
www.caremark.com106-37207A 010219 Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members’ private health information.
Request, Authorization, Exception, Prior, Exception prior authorization request
PRESCRIPTION DRUG MEDICATION REQUEST FORM FAX ... - …
www.highmarkblueshield.com1. Submit a separate form for each medication. 2. Complete ALL information on the form. NOTE: The prescribing physician (PCP or Specialist) should, in most cases, complete the form. 3. Please provide the physician address as it is required for physician notification.